Point-of-Care Fecal Calprotectin Monitoring in Preterm Infants at Risk for Necrotizing Enterocolitis

Nakayuenyongsuk, Warapan; Christofferson, Megan; Stevenson, David K.; Sylvester, Karl G.; Lee, Henry; Park, K.T.

doi:10.1016/j.jpeds.2017.12.069

Cited by 25 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of calprotectin as a marker of intestinal disease in neonates were reported given its utility in inflammatory bowel disease ( 14 , 17 , 18 , 29 – 33 ). Some of the reported FCs could be a marker for intestinal permeability such as early diagnosis and resolution of gastrointestinal illnesses ( 14 , 15 , 17 , 29 , 30 ).…”

Section: Discussionmentioning

confidence: 99%

“…Some of the reported FCs could be a marker for intestinal permeability such as early diagnosis and resolution of gastrointestinal illnesses ( 14 , 15 , 17 , 29 , 30 ). However, FC for the purpose of early diagnosis or prognosis of NEC has conflicting results because of wide variations of cutoff points and wide interindividual and intraindividual variations ( 17 , 18 , 33 , 34 ). We checked FC serially during the neonatal period prospectively and reviewed intestinal distress including suspected and definite NEC via medical records, retrospectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic Changes of Fecal Calprotectin and Related Clinical Factors in Neonates

et al. 2020

View full text Add to dashboard Cite

Objective: Fecal calprotectin (FC) has been widely used for a clinical marker of intestinal inflammation in children and adults. However, the clinical usefulness has not been determined in neonates. The purpose of this study was to investigate the change of FC and associated clinical factors in neonates. Methods and Materials: In total, 146 neonates among 472 admissions to our NICU between 2018 and 2019 were included, and 242 stool samples were collected. FC was measured in the first, second, and third–fourth week after birth, respectively, using commercial ELISA. The clinical characteristics were reviewed from medical records. Statistical analyses were performed to analyze associated factors regarding on changes of fecal calprotectin. Results: A wide range from 5.5 to 6,000 mg/kg of FC was observed in neonates. FCs during neonatal period were not correlated with the gestational age at birth or birth weight. The meconial calprotectin was higher than FCs after 2 weeks of age ( n = 134, 418.06 vs. 243.12 in the second week and 259.58 in the third week after birth). Meconial calprotectin was associated with birth weight and meconium stained amniotic fluid. FC during the neonatal period decreased with postnatal week (−464.93 ± 158.02 at third–fourth week after birth compared with the 1st week, P = 0.004) and breast milk (−337.27 ± 150.51 compared with formula milk, P = 0.026). Conclusion: Fecal calprotectin tended to decrease with postnatal week during the neonatal period, and breast milk could affect more decrease of FC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Dynamic Changes of Fecal Calprotectin and Related Clinical Factors in Neonates

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recent reports have shown that early gut dysbiosis in infants induces enteric inflammation, as exhibited by the increased expression of fecal calprotectin, 4,12 an antimicrobial protein released from infiltrating neutrophils and mucosal macrophages during inflammatory conditions. 13 Indeed, increased fecal calprotectin has been previously identified in preterm infants suffering from intestinal distress, enteropathies, and necrotizing enterocolitis (NEC) 12,14–16 and term infants with colic. 4…”

Section: Introductionmentioning

confidence: 99%

Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants

et al. 2019

View full text Add to dashboard Cite

BackgroundInfant gut dysbiosis, often associated with low abundance of bifidobacteria, is linked to impaired immune development and inflammation—a risk factor for increased incidence of several childhood diseases. We investigated the impact of B. infantis EVC001 colonization on enteric inflammation in a subset of exclusively breastfed term infants from a larger clinical study.MethodsStool samples (n = 120) were collected from infants randomly selected to receive either 1.8 × 1010 CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal. The fecal microbiome was analyzed using 16S ribosomal RNA, proinflammatory cytokines using multiplexed immunoassay, and fecal calprotectin using ELISA at three time points: days 6 (Baseline), 40, and 60 postnatal.ResultsFecal calprotectin concentration negatively correlated with Bifidobacterium abundance (P < 0.0001; ρ = −0.72), and proinflammatory cytokines correlated with Clostridiaceae and Enterobacteriaceae, yet negatively correlated with Bifidobacteriaceae abundance. Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants.ConclusionOur findings indicate that gut dysbiosis (absence of B. infantis) is associated with increased intestinal inflammation. Early addition of EVC001 to diet represents a novel strategy to prevent enteric inflammation during a critical developmental phase.

show abstract

“…Therefore, more data is needed to determine whether a sudden increase in fecal calprotectin can be used as a diagnostic or prognostic biomarker before clinical symptoms occur. Results from recent research showed that 62% of preterm neonates have a high baseline calprotectin (≥200 μ g/g) level throughout the first week after birth [26]. There were also a significant positive linear relationship in the gestationalage < 26weeks group and a significant negative linear relationship in the gestationalage ≥ 26weeks and <30 weeks group between the fecal calprotectin concentration and days after birth [27].…”

Section: Biomarkersmentioning

confidence: 99%

Recent Potential Noninvasive Biomarkers in Necrotizing Enterocolitis

Wang

Tao

Sun

et al. 2019

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Necrotizing enterocolitis (NEC) is a rare but devastating gastrointestinal disease that predominately affects preterm neonates. Numerous studies have revealed that NEC is strongly associated with very low birth weight, degree of prematurity, formula feeding, infection, hypoxic/ischemic injury, and enteric dysbiosis. Given these clinical associations, the search for a deeper understanding of disease pathogenesis has led to an intense interest in the discovery and development of noninvasive biomarkers of NEC from stool, urine, and serum. Biomarkers for NEC may serve at least two general purposes of urgent unmet need: to improve diagnostic accuracy and disease prediction and to reveal the mechanism of the disease. This review will provide an overview of recent research focused on clinical NEC and highlight the advances that were made within the past five years towards the development of noninvasive diagnostic biomarkers.

show abstract

Point-of-Care Fecal Calprotectin Monitoring in Preterm Infants at Risk for Necrotizing Enterocolitis

Cited by 25 publications

References 30 publications

Dynamic Changes of Fecal Calprotectin and Related Clinical Factors in Neonates

Dynamic Changes of Fecal Calprotectin and Related Clinical Factors in Neonates

Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants

Recent Potential Noninvasive Biomarkers in Necrotizing Enterocolitis

Contact Info

Product

Resources

About